PMGC Holdings (ELAB) EBITDA Margin (2022 - 2026)

PMGC Holdings' (ELAB) quarterly EBITDA Margin came in at 292.91% in Q2 2026, up 40.07% quarter-over-quarter from 488.74% in Q1 2026.

Analysis

PMGC Holdings (ELAB) EBITDA Margin (2022 - 2026) Analysis & Trends

PMGC Holdings has disclosed EBITDA Margin across 5 years of filings, most recently posting 292.91% for Q2 2026.

In Q2 2026, EBITDA Margin changed N/A year-over-year to 292.91%; the TTM figure through Jun 2026 stood at 460.35% (changed N/A YoY), while the FY2025 annual figure was 1166.27%, changed N/A from the prior year.
EBITDA Margin came in at 292.91% for Q2 2026 at PMGC Holdings, up from 488.74% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 109.19% in Q3 2022 to a low of 825.82% in Q4 2025.
Average EBITDA Margin over 5 years is 351.25%, with a median of 273.93% recorded in 2024.
Year-over-year, EBITDA Margin surged 31870 bps in 2024 and sank 59460 bps in 2025.
Over 5 years, EBITDA Margin stood at 177.96% in 2022, then gained by 13 bps to 154.73% in 2023, then decreased by 13 bps to 174.38% in 2024, then slumped by 374 bps to 825.82% in 2025, then surged by 65 bps to 292.91% in 2026.
Per Business Quant data, the three most recent EBITDA Margin figures were 292.91% in Q2 2026, 488.74% in Q1 2026, and 825.82% in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Amgen	207.26 Bn	193.27 Bn	7.24 Bn	34.95%
2	Gilead Sciences	179.66 Bn	176.48 Bn	6.22 Bn	-133.21%
3	Vertex Pharmaceuticals	131.52 Bn	123.67 Bn	2.84 Bn	37.40%
4	Regeneron Pharmaceuticals	81.77 Bn	73.78 Bn	3.93 Bn	30.15%
5	Argenx Se	61.15 Bn	55.97 Bn	1.37 Bn	32.54%
6	Moderna	53.55 Bn	48.41 Bn	52.00 Mn	-562.07%
7	Alnylam Pharmaceuticals	33.38 Bn	30.07 Bn	992.69 Mn	17.93%
8	Biogen	31.68 Bn	30.40 Bn	1.96 Bn	-23.56%
9	Roivant Sciences	29.12 Bn	29.12 Bn	1.16 Mn	-25,380.93%
10	PMGC Holdings	2.29 Mn	-16.50 Mn	385,691.00	-292.91%

Historic Data

Download Data